Form 8-K - Current report:
SEC Accession No. 0001558370-23-005110
Filing Date
2023-03-30
Accepted
2023-03-30 16:47:11
Documents
15
Period of Report
2023-03-30
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nrbo-20230330x8k.htm   iXBRL 8-K 42117
2 EX-99.1 nrbo-20230330xex99d1.htm EX-99.1 157931
3 GRAPHIC nrbo-20230330xex99d1001.jpg GRAPHIC 12945
  Complete submission text file 0001558370-23-005110.txt   437692

Data Files

Seq Description Document Type Size
4 EX-101.SCH nrbo-20230330.xsd EX-101.SCH 3265
5 EX-101.LAB nrbo-20230330_lab.xml EX-101.LAB 632
6 EX-101.PRE nrbo-20230330_pre.xml EX-101.PRE 10416
9 EXTRACTED XBRL INSTANCE DOCUMENT nrbo-20230330x8k_htm.xml XML 4880
Mailing Address 200 BERKELEY ST. FL 19 BOSTON MA 02116
Business Address 200 BERKELEY ST. FL 19 BOSTON MA 02116 (857) 702-9600
NeuroBo Pharmaceuticals, Inc. (Filer) CIK: 0001638287 (see all company filings)

EIN.: 472389984 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37809 | Film No.: 23781351
SIC: 2834 Pharmaceutical Preparations